日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

A Real-World Study of Safety, Immunogenicity and Efficacy of Bevacizumab in Patients With Solid Malignancies: A Phase IV, Post-Marketing Study in India

贝伐珠单抗治疗实体恶性肿瘤患者的安全性、免疫原性和疗效的真实世界研究:一项在印度开展的IV期上市后研究

Sinha, Shubhadeep D; Biswas, Ghanashyam; Bheemareddy, Bala Reddy; Chary, Sreenivasa; Thakur, Pankaj; Jain, Minish; Maksud, Tanveer; Pawar, Suraj; Chatterjee, Koushik; Voonna, Murali Krishna; Goel, Anil; Puligundla, Krishna Chaitanya; Lakshmaiah, Kuntegowdanahalli Chinnagiriyappa; Talluri, Leela; Vattipalli, Ramya; Kakkunnath, Sheejith

Enhancement of effector functions of anti-CD20 monoclonal antibody by increased afucosylation in CHO cell line through cell culture medium optimization

通过优化细胞培养基增加 CHO 细胞系中的无岩藻糖基化来增强抗 CD20 单克隆抗体的效应功能

Bala Reddy Bheemareddy, Prakash Narayana Reddy, Kranthi Vemparala, Vijaya R Dirisala

Efficacy, tolerability and safety of darbepoetin alfa injection for the treatment of anemia associated with chronic kidney disease (CKD) undergoing dialysis: a randomized, phase-III trial

达贝泊汀α注射液治疗接受透析治疗的慢性肾脏病(CKD)相关贫血的疗效、耐受性和安全性:一项随机、III期试验

Sinha, Shubhadeep D; Bandi, Vamsi Krishna; Bheemareddy, Bala Reddy; Thakur, Pankaj; Chary, Sreenivasa; Mehta, Kalpana; Pinnamareddy, Vikranth Reddy; Pandey, Rajendra; Sreepada, Subhramanyam; Durugkar, Santosh

Correction to: Efficacy, tolerability and safety of darbepoetin alfa injection for the treatment of anemia associated with chronic kidney disease (CKD) undergoing dialysis: a randomized, phase-III trial

更正:达贝泊汀α注射液治疗接受透析治疗的慢性肾脏病(CKD)相关贫血的疗效、耐受性和安全性:一项随机III期试验

Sinha, Shubhadeep D; Bandi, Vamsi Krishna; Bheemareddy, Bala Reddy; Thakur, Pankaj; Chary, Sreenivasa; Mehta, Kalpana; Pinnamareddy, Vikranth Reddy; Pandey, Rajendra; Sreepada, Subhramanyam; Durugkar, Santosh